[{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"9a54d64d-2889-431d-bba8-38823f83de86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05922930","created_at":"2023-06-28T14:08:31.873Z","updated_at":"2024-07-02T16:34:25.851Z","phase":"Phase 1/2","brief_title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","source_id_and_acronym":"NCT05922930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • TACSTD2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TROP2 expression","tags":["BRCA1 • BRCA2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-14"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"3914247b-96ea-451f-8ee1-b8dc8967ecc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066424","created_at":"2023-10-04T15:10:44.941Z","updated_at":"2024-07-02T16:35:18.780Z","phase":"Phase 1","brief_title":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","source_id_and_acronym":"NCT06066424","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 04/30/2038","primary_completion_date":" 04/30/2038","study_txt":" Completion: 04/30/2040","study_completion_date":" 04/30/2040","last_update_posted":"2024-02-19"}]